| scholarly article | Q13442814 |
| P356 | DOI | 10.1158/0008-5472.CAN-05-2339 |
| P698 | PubMed publication ID | 16849566 |
| P50 | author | Pawel Surowiak | Q60663210 |
| P2093 | author name string | Hermann Lage | |
| Rudolf Hartung | |||
| Uwe Treiber | |||
| Bernd Gansbacher | |||
| Alexander Kaszubiak | |||
| Alexandra Bernshausen | |||
| Klaus Mantwill | |||
| Per S Holm | |||
| Alexa Bieler | |||
| Nadia Köhler-Vargas | |||
| Tanja Dravits | |||
| P433 | issue | 14 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phenotype | Q104053 |
| Adenoviridae | Q193447 | ||
| multiple drug resistance | Q643839 | ||
| chemotherapy | Q974135 | ||
| oncolytic virus | Q1560099 | ||
| P304 | page(s) | 7195-7202 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents | |
| P478 | volume | 66 |
| Q35955387 | A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma |
| Q39861470 | Adenovirus-based virotherapy enabled by cellular YB-1 expression in vitro and in vivo |
| Q38929123 | An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment |
| Q26863779 | Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances |
| Q39863000 | Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment |
| Q34115068 | Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. |
| Q41260269 | Comparative proteomics of exosomes secreted by tumoral Jurkat T cells and normal human T cell blasts unravels a potential tumorigenic role for valosin-containing protein. |
| Q46035877 | Comparision of the cytotoxic effects of birch bark extract, betulin and betulinic acid towards human gastric carcinoma and pancreatic carcinoma drug-sensitive and drug-resistant cell lines. |
| Q34007902 | Identification of internal ribosome entry segment (IRES)-trans-acting factors for the Myc family of IRESs |
| Q33394070 | Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells |
| Q35048886 | Links between the oncoprotein YB-1 and small non-coding RNAs in breast cancer |
| Q40064850 | Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer |
| Q36769180 | Oncolytic viruses in cancer therapy |
| Q39432063 | Oncolytic viruses: adenoviruses. |
| Q41114342 | Regulation on Toll-like Receptor 4 and Cell Barrier Function by Rab26 siRNA-loaded DNA Nanovector in Pulmonary Microvascular Endothelial Cells. |
| Q28293110 | YB-1 as a potential target in cancer therapy |
| Q37360181 | YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells |
| Q36791090 | YB-1 is a Transcription/Translation Factor that Orchestrates the Oncogenome by Hardwiring Signal Transduction to Gene Expression |
| Q41133867 | YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder? |
| Q39698461 | [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model |
Search more.